Stimulation of the nervous system could replace drugs for inflammatory and autoimmune conditions
Theuse of nerve-stimulating electronic devices to treat inflammation and reversedisability is laying the foundation for a new discipline called bioelectronicmedicine. It is being tested in clinical studies of patients with rheumatoid
arthritis and other diseases. It is based on a deceptively simple concept of
harnessing the body’s natural reflexes to develop an array of effective, safe
and economical alternatives to many pills and injectable drugs. By precisely
targeting the biological processes underlying disease, this nerve-stimulating
technology should help avoid the troublesome side effects of many drugs.
THE
REFLEX CIRCUIT
Heat,
touch, pressure, light and the presence of specific molecules generate an
electrical signal in nerve cells called sensory neurons. This electrical
information is transmitted to “interneurons,” another type of nerve cell in
the central nervous system that passes the incoming impulse along to motor
neurons, which complete the third and final stage in the simple reflex circuit.
The subsequent firing of the motor neuron sends electrical signals back to
the body’s muscles and organs, triggering behaviors ranging
from the withdrawal of a finger from a hot plate to the dilation of an
airway during a three-mile run.
Simple
reflex circuits harmonize the activity of individual organs,
so that you do not have to consciously plan the minute organs, so that you
do not have to consciously plan the minute actions that keep your body
functioning efficiently. When you leap from a chair and run up the stairs to
answer the ring of a telephone, you do not have to think about coordinating
your respiration, heart rate and blood pressure. Reflexes take care of all the
essentials, matching organ function to the body’s needs, whether resting
comfortably or running at full speed.
Charles
Scott Sherrington (1857–1952), the Nobel Prize–winning British physiologist,
proposed that simple reflexes made up of neural circuits are the basic building
blocks of the nervous system. The combined output of millions of nerve signals
that control reflexes directs the functioning of the body’s organs. But
Sherrington did not address one lingering question: How do the electrical
signals that course through motor neurons actually control organ function? The
answer is relatively simple. In effect, they produce “drugs.” Neurons transmit
information along nerve fibers, or axons, the long, wirelike extensions that
terminate in the organ being regulated. At the very end of the axon lies the
“synapse,” a word coined by Sherrington. The motor neuron’s axon on one side of
the synapse does not physically touch the nerve or organ cells on the opposite
side of the narrow gap called the synaptic cleft. Instead the arrival of the
electrical signals at the end of the axon stimulates release of
neurotransmitters that diffuse across the synaptic cleft and bind to receptors,
docking sites on the target nerve or organ cells. Chemical neurotransmitter
molecules latch on to receptors at the other side of this cleft to alter the behavior
of the targeted cells, changing their function. It turns out that many drugs
work in a similar manner.
The
pharmaceutical industry invests billions of dollars to design, synthesize and
develop new chemicals as experimental drugs that, like neurotransmitters, are
nothing more than molecules that interact with receptors. Many blockbuster
drugs selectively bind to specific receptors that modify metabolic activity
and turn on genes in selected cells. But drugs can have dangerous side effects.
Once swallowed or injected, pharmaceuticals travel throughout the body, where
they may produce undesired consequences when interacting with cells that are not
their intended targets.
Using
a device to send signals down a nerve to stimulate production of druglike
neurotransmitters offers a distinct advantage. The body’s self-made drugs
deliver chemicals to specific tissues in precise, nontoxic amounts at just the
right time, diminishing the occurrence of side effects.
AN
ACCIDENTAL DISCOVERY
By
the late 1990s a new class of pharmaceutical called monoclonal antibodies
were being used to treat patients with rheumatoid arthritis, inflammatory bowel
disease and other disorders. Monoclonal antibodies, which Dr. Tracey and his
colleagues helped to pioneer, can alleviate the pain, swelling, tissue
destruction, and other symptoms of inflammation caused by the overproduction of
TNF and other molecules. For many patients, it offers their only chance for a
normal life. But success has come with soaring costs. Drug bills range from
$15,000 to $30,000 annually for a single patient, even though anti-TNF is
ineffective in up to 50 percent of patients. Perhaps most worrisome to patients
and their caregivers, these drugs can cause dangerous, even lethal, side
effects.
Initially
Dr. Tracey’s team reasoned that perhaps CNI-1493 activated the brain’s
pituitary gland at the base of the brain to stimulate production of hormones,
including steroids—or glucocorticoids—that in turn inhibited TNF production in
distant organs. Alas, after surgically removing the pituitary gland in rats and
repeating the experiments, we found that CNI-1493 injected into the brain
still inhibited TNF. This result meant that the pituitary gland did not convey the
signal that turned off TNF production in the body. Searching for another
explanation, they began to consider the improbable possibility that motor
neurons exiting the brain carried electrical signals to inhibit TNF in the rest
of the body.
Sometimes gender roles are so deeply embedded in our society we hardly notice them. Ashton Kutcher picked up on one such example over the weekend — and he’s not wrong.
but think about how difficult it is for single dads. like seriously
